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Background: Whether paricalcitol (PCT) reduces proteinuria in the presence of intensified inhibition of
Renin-Angiotensin-System (RAS) is poorly studied. We evaluated the antiproteinuric effect of PCT in non-dialysis
chronic kidney disease (CKD) patients with proteinuria greater than 0.5 g/24 h persisting despite anti-RAS therapy
titrated to minimize proteinuria in the absence of adverse effects.
Methods: Forty-eight CKD patients were studied in the first six months of add-on oral PCT (1 mcg/day) and three
months after drug withdrawal.
Results: Males were 87.5%, age 63 ± 14 yrs, systolic/diastolic blood pressure (BP) 143 ± 22/78 ± 11 mmHg, eGFR
29.7 ± 14.5 mL/min/1.73 m2, diabetes 40%, and cardiovascular disease 38%. At referral in the center (28 months
prior to study baseline), proteinuria was 2.44 (95% CI 1.80-3.04) g/24 h with 6 patients not receiving any anti-RAS
and 42 treated with a single agent, at low dosage in most cases. At study baseline, twenty patients were under
2–3 anti-RAS drugs while twenty-eight received 1 agent at full dose and proteinuria resulted to be reduced
versus referral to 1.23 g/24 h (95%CI 1.00-1.51). Six months of add-on PCT significantly decreased proteinuria to
0.61 g/24 h (95%CI 0.40-0.93), with levels less than 0.5 g/24 h achieved in 37.5% patients, in the absence of changes
of BP and GFR. Proteinuria recovered to basal value after drug withdrawal. The extent of antiproteinuric response to
PCT was positively associated with diabetes, eGFR and daily Na excretion (R2 = 0.459, P < 0.0001). PTH decreased
from 201 (IQR 92–273) to 83 (IQR 50–189) pg/mL.
Conclusions: In CKD patients, add-on PCT induces a significant reduction of proteinuria that is evident despite
intensified anti-RAS therapy and larger in the presence of diabetes, higher GFR and unrestricted salt intake.
Keywords: Angiotensin converting enzyme inhibitor, Angiotensin II receptor blocker, Renin inhibitor, Paricalcitol,
Chronic kidney disease, ProteinuriaBackground
Proteinuria is a well recognized surrogate outcome for
long-term prognosis in patients with chronic kidney dis-
ease (CKD) [1]. The magnitude of proteinuria predicts
in fact renal and cardiovascular (CV) events [1-3], and,
more important, reduction is associated with slowing of
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reproduction in any medium, provided the orInhibition of the renin-angiotensin system (RAS) is the
cornerstone of treatment in proteinuric patients with the
effect being largely independent of blood pressure (BP)
control [1,4-6]. However, the high complexity of the sys-
tem with multiple-level escape mechanisms prevents ad-
equate suppression [7,8]. Indeed, monotherapy with
either angiotensin converting enzyme inhibitor (ACEi)
or angiotensin receptor blocker (ARB) decreases pro-
teinuria by about 30% [9]. Multiple blockade of RAS
with either two or three drugs allows an additional dec-
rement of proteinuria which is however still limited and
heterogeneous, with many patients being left withral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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teinuric strategies aimed at attaining remission of pro-
teinuria (<0.5 g/24 h) are sought.
In the last decade, experimental evidence has been col-
lected on an important renoprotective role of vitamin D
hormone and its analogs [12,13]. Furthermore, rando-
mized clinical trials in non-dialysis CKD have evidenced
that paricalcitol (PCT), the low-calcemic vitamin D ana-
log currently used in Europe to prevent and treat
secondary hyperparathyroidism, also acts as antiprotei-
nuric agent when added to standard anti-RAS therapy
with a single agent [14-18]. However, evidence on the
antiproteinuric effect of PCT in the presence of intensi-
fied anti-RAS therapy is limited [17]. This question is
critical for daily nephrology practice because intensified
anti-RAS therapy, while being possibly contraindicated
in patients with absent or low-degree proteinuria, is war-
ranted in patients with proteinuric CKD treated in renal
clinics [11,19,20].
Aim of this study was to verify the antiproteinuric
response to PCT in adult CKD patients with residual
proteinuria persisting after maximal tolerated anti-RAS
therapy.
Methods
This is a prospective observational study conducted in
CKD patients regularly attending three nephrology out-
patient clinics. The study was approved by the Institu-
tional Review Board of the participating centers (L.D.N.,
G.C. and R.M.: AOU-Second University of Naples; A.G.:
ASL ROMA G; D.R.: AOU-University Federico II of
Naples) and all patients gave informed consent.
Characteristics of centers
The three participating centers share a protocol for man-
agement of CKD patients. Patients are always seen by the
same nephrologist since the first visit in the center (refer-
ral visit). Office systolic and diastolic BP target is <130 and
<80 mmHg, respectively. If at referral the patient is identi-
fied as having white coat hypertension (WCH), that is,
BP ≥130/80 in office and normal (<125/75 mmHg) 24 h
ambulatory BP (ABP) [21,22], office BP target is less re-
strictive being equal to 130/80 mmHg. In the three centers,
ABP is performed by using Spacelabs 90207 monitors.
All patients receive personalized dietary regimens to
limit dietary salt (<6 g NaCl/day) and protein (≤0.8 g/kg
body wt/day), and to avoid food and beverages contain-
ing high amounts of potassium. They also periodically
undergo to serum bicarbonate testing to diagnose and
treat metabolic acidosis. Compliance to drugs is evalu-
ated at each visit in the clinic by means of specific
questions on assumption of pharmacological therapy
directed to the patient and family members. Specifically,
physicians ask the number of times the patient had nottaken the prescribed medications in the last two weeks;
the patient is identified as poorly compliant to therapy,
and therefore excluded from any study, if the missing
rate is ≥20%.
Intensification of anti-RAS therapy
In the three centers, anti-RAS therapy is titrated to
achieve remission of proteinuria (<0.5 g/24 h) in the ab-
sence of adverse effects (symptomatic hypotension or
systolic blood pressure <100 mmHg, acute eGFR de-
crease >30% or serum potassium >5.5 mmol/L).
Participating nephrologists first administer a single
anti-RAS agent (either ACEi or ARB), titrated to the full
dose defined according to the manufacturer’s recom-
mendations in Italy; if proteinuria still persists above the
target we combine ACEi with ARB and/or add Aliskiren
(this drug is not used anymore in combination with
other anti-RAS drugs according to the recommendations
of the European Medicines Agency and FDA released on
February and April 2012, respectively). Anti-aldosterone
drugs are used as additional antiproteinuric agents only
when GFR is ≥ 60 mL/min/1.73 m2. In the case of low
BP levels, antihypertensive drugs other than anti-RAS
are downtitrated.
Selection criteria
From September 2010 to January 2011, we selected
consecutive adult CKD patients under nephrology care
from at least six months in the three participating cen-
ters with eGFR <60 mL/min/1.73 m2 (no dialysis-no
transplant), proteinuria >0.5 g/24 h on two consecutive
visits (30 days apart) and under intensified anti-RAS
therapy unchanged from ≥3 months. Exclusion criteria
were steroid/ immunosuppressive treatment or eGFR
change >30% in the past 3 months, PTH levels <20 pg/mL,
serum phosphorus >5.0 mg/dL, serum calcium (adjusted
for albumin) >10.0 mg/dL, active malignancy.
Add-on paricalcitol
Data were collected at baseline (prior to first administra-
tion of PCT), during administration of oral PCT (after 3
and 6 months), and three months after PCT withdrawal.
PCT was administered at starting dosage of 1 mcg/day
(8:00–9:00 a.m.); this dosage was chosen as it is not
associated with excessive decline of parathyroid hor-
mone (PTH) levels in most patients [16,17]. During the
study, investigators were allowed to modify the dosage
of PCT on the basis of PTH and proteinuria levels.
At each visit of the study, nephrologist performed
physical examination and BP measurement. Two con-
secutive 24 h-urine collection were required and results
averaged. Urine collections were considered inaccurate,
and repeated, if the value of measured creatinine excre-
tion rate fell outside the normal range. Blood and urinary
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was estimated by the four-variable MDRD equation.
Statistics
Variables are reported as mean and standard deviation
(SD) or as median and interquartile range (IQR). Pro-
teinuria values are expressed as geometric mean and
95% confidence interval (CI) because of their positively
skewed distribution. Means are compared by paired or
unpaired Student t test and McNemar or chi-square test
for categorical variables. ANOVA for repeated measures
with Bonferroni as post-hoc test are also used where ap-
propriate. Multivariate linear regression analysis was also
performed to identify the predictors of antiproteinuric
response to PCT (percent change at month 6 of 24-h
proteinuria from baseline). A two-tailed P-value <0.05 is
considered significant. Data are analyzed using SPSS
12.0 (SPSS Inc, Chicago, IL, USA).
Results and discussion
Results
We studied 48 Caucasian patients out of the 76 identi-




Age (years) 63 ± 14 6
Gender (M:F) 42:6 2
Body Mass Index (Kg/m2) 27.6 ± 4.4 2
Diabetes (% pts) 19 (39.6) 1
Previous CV events (% pts) 18 (37.5) 1










25-OH vitamin D (ng/mL) 18.8 ± 10.0 1
eGFR (mL/min/1.73 m2) 29.7 ± 14.5 3
Serum albumin (g/dL) 4.1 ± 0.4 4
Proteinuria (g/day) 1.23 (1.00-1.51) 1
UNaV (mEq/day) 161 ± 63 1
Systolic BP (mmHg) 143 ± 22 1
Diastolic BP (mmHg) 78 ± 11 7
Antihypertensive Drugs (n) 3.6 ± 1.4 3
Anti-RAS per patient (n) 1.6 ± 0.7 1
Furosemide (%) 24 (50.0) 1
Furosemide dose (mg/d) 63 ± 30 6
CCB (%) 25 (52.1) 1
Beta Blocker (%) 27 (56.3) 1
Data are mean ± SD or percentage or geometric mean and (95% confidence interva
hypertensive nephropathy; APKD, autosomal polycystic kidney disease; eGFR, 4-vari
CCB Calcium Channel Blocker.fact excluded because of recent immunosuppressive
treatment (n = 8), acute GFR change (n = 8), poor com-
pliance to therapy (n = 7), low PTH (n = 5).
At first visit in the center (referral), performed
28 months on median (IQR 16–40) prior to add-on PCT
(study baseline), patients had eGFR 38 ± 18 mL/min/
1.73 m2 and proteinuria 2.44 (95% CI 1.80-3.04) g/24 h.
Office BP was 148 ± 18/83 ± 13 mmHg while 24 h ABP
was 133 ± 17/76 ± 11 mmHg, with 43% patients being
identified as having WCH. At referral, the mean number
of antihypertensive drugs was 2.8 ± 1.0; forty-two patients
were treated with a single anti-RAS drug, at low dosage in
90% cases, while the remaining six patients were anti-RAS
naïve. In the first months after referral visit, four patients
had been treated with immunosuppressive agents.
Table 1 shows the main basal characteristics of
patients. Patients showed a high-risk profile as evidenced
by the advanced age, high BMI and the large prevalence
of diabetes and CV disease. Adherence to prescribed low
salt diet (Na excretion ≤100 mmol/24 h) was low (19%).
The increase in the number of BP lowering drugs,
observed at baseline versus referral visit, was mainly due







4.1 ± 11.5 62.7 ± 16.9 0.735
2:2 20:4 0.666
7.9 ± 3.8 27.2 ± 5.1 0.593
4 (58.3) 5 (20.8) 0.017
1 (45.8) 7 (29.2) 0.371











9.9 ± 8.7 17.6 ± 11.2 0.433
5.5 ± 16.0 23.9 ± 10.1 0.004
.0 ± 0.5 4.2 ± 0.4 0.241
.14 (0.81-1.61) 1.32 (1.02-1.71) 0.501
83 ± 60 141 ± 52 0.012
46 ± 19 141 ± 24 0.453
8 ± 11 78 ± 12 0.980
.3 ± 1.4 3.8 ± 1.4 0.224
.5 ± 0.7 1.6 ± 0.8 0.848
4 (58.3) 10 (41.7) 0.387
0 ± 32 64 ± 31 0.742
3 (54.2) 12 (50.0) 1.00
7 (70.8) 10 (41.7) 0.080
l). CV, cardiovascular; DN, diabetic nephropathy; GN, glomerulonephritis; HN,
able MDRD estimated GFR; BP, blood pressure; RAS, renin angiotensin system;
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they received either ACEi + ARB (n = 11) or ARB +Aliski-
ren (n = 1) or ACEi + Aliskiren (n = 1) or ACEi + ARB +
Aliskiren (n = 7). Intensification of anti-RAS therapy was
also obtained in the twenty-eight patients administered a
single anti-RAS agent; at referral, in fact, these drugs were
not used in four or used at low dosage in the remaining
twenty-four patients while at baseline all patients were
treated with anti-RAS at full dose. In these 28 patients,
combined therapy was considered unfeasible because, dur-
ing the previous follow up in the center, adding the second
anti-RAS agent had been associated with documented
acute GFR decline (n = 8), hypotension (n = 7), hyperka-
lemia (n = 13). As compared with patients under com-
bined anti-RAS therapy, those receiving anti-RAS
monotherapy were older (69 ± 11 vs 55 ± 14 years) and
had lower levels of eGFR (26 ± 12 vs 35 ± 17 mL/min/
1.73) (P < 0.05 for both).
As reported in Table 2, add-on PCT was associated
with a progressive decline in PTH levels that, however,
did not decrease below the lower limit of normal range
(20 pg/mL) in any patient. No significant change of alka-
line phosphatase (ALP) levels was observed, with only
two patients at month 3 and one patient at month 6
showing ALP levels below the lower limit of normal
range (40 IU/L). Serum calcium and phosphate remained
within normal range in all patients but one that had a
single episode of hyperphosphatemia (6.4 mg/dL) at
month 3 due to excessive phosphorus intake. In this
patient, PCT was temporarily withdrawn and re-started
at 1 mcg/day within one month after successfully re-
inforcing dietary advices and administering a phosphate
binder. Binders were constantly administered through-
out follow up in seven patients.
Add-on PCT induced a progressive decrease of pro-
teinuria (Table 2). Remission of proteinuria to values
<0.5 g/24 h was achieved in 14.6% at month 3, and in
37.5% by month 6 (P = 0.007 vs month 3). These resultsTable 2 Changes of main parameters during Paricalcitol (PCT
withdrawal (n = 42)
Basal Mon
SBP/DBP (mmHg) 143 ± 22/78 ± 11 137 ±
eGFR (mL/min/1.73 m2) 29.7 ± 14.5 27.3
Serum potassium (mmol/L) 4.6 ± 0.7 4.8 ±
PTH (pg/mL) 201 (92–273) 140 (
ALP (IU/L) 155 ± 96 148 ±
Serum Calcium (mg/dL) 9.3 ± 0.6 9.3 ±
Serum Phosphate (mg/dL) 3.9 ± 0.7 3.9 ±
Proteinuria (g/24 h) 1.23 (1.00-1.51) 0.85
UNaV (mmol/24 h) 161 ± 63 144 ±
Data are mean ± SD or median and interquartile range (PTH) or geometric mean an
pressure; eGFR, 4-variable MDRD estimated GFR; ALP, Alkaline Phosphatase; UNaV, 2were obtained in the presence of an unchanged antihy-
pertensive therapy (mean number from baseline to
month 6 was 3.6 ± 1.4, 3.6 ± 1.4 and 3.4 ± 1.4, respect-
ively) and a small reduction in the number of anti-RAS
(1.6 ± 0.7, 1.4 ± 0.8 and 1.4 ± 0.8, respectively). The me-
dian reduction of proteinuria after six months of PCT
was 32% (IQR 11–52). No correlation was found be-
tween percentual change in proteinuria and systolic BP
(r = 0.146, P = 0.324).
Table 1 reports the basal characteristics of good and
poor responders to PCT, as defined according to the ex-
tent of proteinuria reduction around the median value
(≥30% and <30%, respectively). Median reduction of pro-
teinuria was 57% (IQR: 46–72) in good responders and
11% (from −8 to 22) in poor responders. Good respon-
ders showed greater prevalence of diabetes, and higher
eGFR and 24 h urinary sodium excretion. Multiple linear
regression analysis of antiproteinuric response as con-
tinuous variable (model summary: R2 = 0.459, P < 0.0001)
confirmed the greater antiproteinuric effect in the pres-
ence of diabetes (P = 0.022), higher eGFR (P = 0.004) and
higher daily Na excretion (P = 0.005) while association
with age and gender was not significant.
The first dose of PCT (1 mcg/day) did not change
throughout the six months of follow up in 40/48
patients, halved in three patients (low PTH or gastro-
intestinal intolerance), and doubled in five (increasing
PTH and/or proteinuria).
To verify the dependence of proteinuria reduction on
PCT, we evaluated the change of proteinuria three
months after drug withdrawal. This analysis was not pos-
sible in six patients because, after month 6, three of them
started hemodialysis, two had a flare of underlying glom-
erulonephritis that required immunosuppressive therapy,
and one moved to other town. In the 42 patients under-
going PCT withdrawal, proteinuria recovered to baseline
(Figure 1). In these patients, median PTH was 206 (102–
270) pg/mL at baseline, 90 (51–188) pg/mL at month 6) in the whole cohort (n = 48) and three months after
th 3 Month 6 PCT withdrawal
15/78 ± 10 138 ± 17/79 ± 10 134 ± 16/77 ± 9
± 15.5 27.5 ± 16.2 26.9 ± 15.3
0.7 4.8 ± 0.6 4.7 ± 0.6
64–226)* 83 (50–189)* 111 (74–184)*
86 143 ± 93 135 ± 95
0.5 9.4 ± 0.4 9.3 ± 0.6
0.8 3.9 ± 0.7 3.9 ± 0.7
(0.59-1.21)* 0.61 (0.40-0.93)* 1.12 (0.86-1.44)
55 149 ± 65 157 ± 66
d 95% confidence interval (proteinuria). SBP/DBP, systolic/diastolic blood
4 h urinary Na excretion. *P < 0.05 vs basal.
Figure 1 Proteinuria levels measured in 42 patients before (baseline), after add-on Paracalcitol (Month 6), and after three-month drug
withdrawal. Data are geometric mean and 95% confidence interval. See text (Results) for missing patients.
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month 6 and withdrawal versus baseline).
Discussion
The co-existence of proteinuria >0.5 g/24 h and GFR
<60 mL/min/1.73 m2 identifies a subgroup of CKD
patients which carries the highest cardio-renal risk [1-3].
In these patients, minimizing RAS activity is a main tar-
get of treatment [1,3,6]. Such a subgroup of CKD
patients was the object of the current study. Enrolled
subjects were in fact encumbered by multiple risk factors
and significant proteinuria despite intensified anti-RAS
treatment. This therapeutic feature represents the main
difference with the previous studies on antiproteinuric
effect of PCT where patients did not consistently
undergo intensification of anti-RAS therapy prior to
add-on PCT [14-17]. In our cohort, the preliminary in-
tensification of anti-RAS therapy during the interval be-
tween referral and study baseline (two years on median)
is testified by the marked decrease of proteinuria in the
absence of major changes of antihypertensive therapy
other than anti-RAS. As a consequence of the predom-
inant use of anti-RAS versus other drugs, only a mild
decline of BP values from the referral visit was observed.
The large prevalence of WCH (43%), that is expected in
tertiary nephrology care [23], further restrained partici-
pating nephrologists from intensifying antihypertensive
agents other than anti-RAS. Of note, in this observa-
tional study in outpatient clinics, we enrolled patients
under maximal tolerated anti-RAS therapy. In this re-
gard, it is noteworthy that patients treated with a single
anti-RAS, that were older and with more advanced
CKD, had documented side effects when implementation
of combined treatment was attempted. Under the pecu-
liar condition of intensified anti-RAS therapy, add-on
PCT induced a 32% reduction of proteinuria, with asubstantial portion of patients (38%) showing remission
of proteinuria (<0.5 g/24 h).
Assessment of underlying pathophysiological mechan-
isms goes beyond the original purpose of the study. We
hypothesize that the additive antiproteinuric effect of
PCT may be at least in part related to more effective
RAS inhibition. Indeed, experimental data converge to
indicate that PCT blunts the compensatory increase of
renin synthesis secondary to the disruption of the feed-
back inhibition loop occurring during chronic adminis-
tration of anti-RAS agents [12,13,24]. Therefore, the
detrimental effects on the kidney of renin, that can
occur also independently from AII [7], may be limited in
the course of add-on PCT therapy. Nevertheless, anti-
inflammatory effects, direct and indirect (mediated by
suppression of intrarenal RAS activity), as well as lessen-
ing of podocyte injury, cannot be excluded [12,13,25,26].
The extent of antiproteinuric effect of PCT was
greater in the presence of higher GFR, diabetes and
higher salt intake (Table 1). These associations persisted
when considering the proteinuria change as continuous
variable in the multiple regression analysis adjusted for
age and gender. The influence of GFR is expected, being
conceivably related to the amount of irreversible pro-
teinuria that increases in parallel with advancing nephro-
sclerosis [2]. Therefore, in the specific context of this
study including patients with GFR <60, the more is pre-
served renal function the greater is the reduction of pro-
teinuria. In this regard, recent studies have disclosed
that also less expensive interventions such as nutritional
vitamin D repletion or administration of calcitriol, that
is a less potent and more calcemic vitamin D analog
[27], reduce proteinuria in patients with milder degrees
of renal disease, such as microalbuminuric diabetic
nephropathy with moderate GFR impairment and IgA
nephropathy with close-to-normal GFR [28,29].
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of PCT evidenced in diabetics; the higher response may
be related to the greater activity of intrarenal RAS
[30,31], and/or to the specific positive effects of PCT on
glomerular barrier [26]. Interestingly, recent studies have
also evidenced an association between decrements of al-
buminuria and urinary TGF-β in type 2 diabetics treated
with cholecalciferol [28].
On the other hand, more puzzling is the positive rela-
tionship between antiproteinuric response and salt in-
take. Indeed, it is well known that high salt intake blunts
the beneficial effects of anti-RAS therapy [32,33]. As in
the current study, also the VITAL trial showed enhanced
antiproteinuric effect of add-on PCT in diabetic CKD
patients under standard anti-RAS therapy when salt in-
take was high [17]. We obtained similar data when we
evaluated the antiproteinuric effect of aliskiren given on
the top of dual RAS blockade [11]. On this basis, we can
therefore hypothesize that the greater antiproteinuric
effect of PCT in patients at higher sodium intake
could be explained by the suboptimal antiproteinuric
efficacy of anti-RAS under these conditions. Con-
versely, when patients adhere to sodium restriction,
the antiproteinuric response to anti-RAS is already ele-
vated and the antiproteinuric effect of add-on PCT is
therefore limited. Independent of underlying mechan-
ism, the finding is of great clinical interest as the ma-
jority of patients are not compliant to salt restriction
even if followed in renal clinics [2].
The significant antiproteinuric effect of PCT was not
impaired by major adverse effects, thus extending to this
subgroup of high-risk and poly-treated patients the fa-
vorable safety profile of PCT previously reported [13-18].
PTH and ALP remained in the normal range in most
patients. This finding supports the experimental evidence
that low-dose PCT, given in the absence of exogenous
calcium loading, is not associated to excessive suppres-
sion of bone turnover [34].
Interpretation of results is limited by the small sample
size and the absence of control group; nevertheless, the
remarkable antiproteinuric response and the recovery of
proteinuria to baseline after three months of drug with-
drawal support the validity of our observations. As re-
gard the recovery of proteinuria after drug withdrawal,
however, we cannot exclude some degree of escape of
proteinuria which is a not a uncommon finding when in-
hibition of RAS is intensified (7,8,11). Furthermore,
more prolonged follow up is required to verify efficacy
and safety of this approach over the long-term. Finally,
we did not assess systemic RAS activity. While it pre-
cludes from gaining insights into the mechanism(s) of
the antiproteinuric effects of add-on PCT, the antihyper-
tensive poly-therapy and the outpatient setting of the
study, with the consequent uncontrolled externalbalance of sodium, prevent any meaningful evaluation of
this system in our patients. However, it is well known
that intrarenal rather than systemic RAS acts as the
major control mechanism [7,8].
Conclusions
This study suggests that in patients with low GFR and per-
sisting proteinuria despite maximal tolerated anti-RAS
therapy: (1) add-on PCT safely allows a reduction of pro-
teinuria with a remarkable achievement of levels <0.5 g/
24 h in more than one-third of cases, (2) antiproteinuric
response to PCT is greater in diabetics, patients with
higher GFR and in the presence of unrestricted salt intake.
PCT therefore represents a potential additional thera-
peutic option to be considered when intensified anti-
RAS treatment is not completely efficacious or unfeasible
because of adverse effects. Whether the antiproteinuric
effect of PCT translates into improvement of prognosis
of these high-risk patients is worth investigating.
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